N/A
Completed N=16
Treatment Modification to Reduce Symptom Burden in Hemodialysis
Source: ClinicalTrials.gov NCT01775800 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Number of Participants Recruited, Consented, Randomized and Completed — 51; 16; 16; 16 Participants
Summary
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Recruited, Consented, Randomized and Completed |
51; 16; 16; 16 | — |
| SECONDARY Symptom Burden |
9.00; 13.25; 11.00; 9.88 | — |
Eligibility Criteria
Inclusion Criteria
- hemodialysis patient
- transplant ineligible
Exclusion Criteria
- dementia
- unable to answer questionnaires for any reason
Data sourced from ClinicalTrials.gov (NCT01775800). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.